BRPI0512993A - uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto - Google Patents

uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto

Info

Publication number
BRPI0512993A
BRPI0512993A BRPI0512993-1A BRPI0512993A BRPI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A
Authority
BR
Brazil
Prior art keywords
contraception
pharmaceutically useful
antagonist
female
childbirth
Prior art date
Application number
BRPI0512993-1A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Andrew Fensome
Casey Cameron Mccomas
Edward George Melenski
Michael Anthony Marella
Jay Edward Wrobel
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0512993A publication Critical patent/BRPI0512993A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UM ANTAGONISTA DE PR, KIT FARMACEUTICAMENTE úTIL, E, MéTODO DE CONTRACEPçãO EM UMA FêMEA EM IDADE DE PARTO Um método de contracepção é fornecido que envolve a liberação de 21 a 27 dias consecutivos de um ou mais antagonistas de PR na ausência de uma progestina, estrogênio ou outro composto esteróide, seguido por 1 a 7 dias sem nenhum agente ativo. Também é descrito um kit farmaceuticamente útil para facilitar a liberação deste regime.
BRPI0512993-1A 2004-07-07 2005-07-06 uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto BRPI0512993A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29
PCT/US2005/023798 WO2006017075A1 (en) 2004-07-07 2005-07-06 Progesterone receptor antagonist contraceptive regimens and kits

Publications (1)

Publication Number Publication Date
BRPI0512993A true BRPI0512993A (pt) 2008-04-22

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512993-1A BRPI0512993A (pt) 2004-07-07 2005-07-06 uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto

Country Status (20)

Country Link
US (1) US20060009509A1 (pt)
EP (1) EP1773323A1 (pt)
JP (1) JP2008505906A (pt)
KR (1) KR20070039912A (pt)
AR (1) AR049664A1 (pt)
AU (1) AU2005271974A1 (pt)
BR (1) BRPI0512993A (pt)
CA (1) CA2571198A1 (pt)
CR (1) CR8800A (pt)
EC (1) ECSP077131A (pt)
GT (1) GT200500186A (pt)
IL (1) IL180238A0 (pt)
MX (1) MXPA06014580A (pt)
NO (1) NO20070377L (pt)
PA (1) PA8638501A1 (pt)
PE (1) PE20060485A1 (pt)
RU (1) RU2006144069A (pt)
SV (1) SV2006002166A (pt)
TW (1) TW200605880A (pt)
WO (1) WO2006017075A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20060009428A1 (en) 2004-07-07 2006-01-12 Wyeth Cyclic progestin regimens and kits
CA2573266C (en) 2004-07-09 2011-11-08 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
RS55331B1 (sr) 2009-04-14 2017-03-31 Hra Pharma Lab Postupak za kontracepciju po potrebi
WO2010146488A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Bicyclic and tricyclic compounds as kat ii inhibitors
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MX2012004373A (es) 2009-10-14 2012-06-28 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol.
CA2788440A1 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
DK2646443T3 (en) 2010-12-01 2014-11-17 Pfizer CAT-II inhibitors
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2014140217A1 (en) * 2013-03-14 2014-09-18 Laboratoire Hra-Pharma Method for scheduling ovulation
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
CN107847506A (zh) 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
US20060009509A1 (en) 2006-01-12
MXPA06014580A (es) 2007-03-23
JP2008505906A (ja) 2008-02-28
EP1773323A1 (en) 2007-04-18
NO20070377L (no) 2007-02-07
RU2006144069A (ru) 2008-08-20
ECSP077131A (es) 2007-02-28
WO2006017075A1 (en) 2006-02-16
AU2005271974A1 (en) 2006-02-16
CR8800A (es) 2007-08-28
GT200500186A (es) 2006-03-02
CA2571198A1 (en) 2006-02-16
SV2006002166A (es) 2006-05-09
KR20070039912A (ko) 2007-04-13
IL180238A0 (en) 2007-07-04
PE20060485A1 (es) 2006-06-24
PA8638501A1 (es) 2006-07-03
TW200605880A (en) 2006-02-16
AR049664A1 (es) 2006-08-23

Similar Documents

Publication Publication Date Title
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
BRPI0512991A (pt) uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
ES2602823T3 (es) Proceso para la preparación de drospirenona
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
BRPI0505524A (pt) método passìvel de utilização com um poço subterráneo, sistema passìvel de utilização com um poço subterráneo, e ferramenta passìvel de utilização com um poço subterráneo
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
DE602004017045D1 (de) Graduierte östrogen-kontrazeptiva
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BRPI0709057C1 (pt) veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
ITMI20040367A1 (it) Processo per la preparazione di drospirenone
SG166107A1 (en) Quadraphasic continuous graduated estrogen contraceptive
CO5631449A2 (es) Nuevos esteres de etonogestrel
PE20080995A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
BR0215064A (pt) Agonistas receptores seletivos de dopamina d3 para o tratamento de disfunção sexual
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
PE20010579A1 (es) Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos
BR0116127A (pt) Composto, composição farmacêutica, uso de um composto, e, conjunto para a contracepção masculina
AR069195A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
BRPI0506408A (pt) instrumento de aprumamento para embolso de paredes e nivelamento de contra pisos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]